Respiratory VirusCoronavirusCOVID-19VaccinesPublications Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial – The Lancet By Rob LW - 23rd May 2020 0 12 Facebook Twitter WhatsApp Email Click here to view original web page at Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial – The Lancet Share this:Click to share on LinkedIn (Opens in new window)Click to share on Twitter (Opens in new window)Click to share on Facebook (Opens in new window)Click to share on WhatsApp (Opens in new window)Click to email this to a friend (Opens in new window)Click to print (Opens in new window) Related
